共 54 条
[1]
Llovet JM(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med. 359 378-390
[2]
Ricci S(2010)Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial JAMA. 304 2154-2160
[3]
Mazzaferro V(2012)The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review Surgery. 151 860-870
[4]
Abou-Alfa GK(2012)Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection Br J Surg. 99 558-565
[5]
Johnson P(2012)Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases Ann Surg. 256 746-752
[6]
Knox JJ(2011)Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology. 140 497-507
[7]
Quan D(2013)Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses Radiology. 269 603-611
[8]
Gallinger S(2007)Radioembolization with yttrium-90 microspheres: review of an emerging treatment for liver tumors Future Oncol. 3 73-81
[9]
Nhan C(2010)Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology. 138 52-64
[10]
Evrard S(2014)A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases J Cancer Res Clin Oncol. 140 537-547